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autonomic function on health related quality
of life, vocational functioning and health care
utilisation in acute coronary syndrome patients:
the ADVENT study protocol
John C Oldroyd1*, Sheila Cyril1, Bhanuja S Wijayatilaka1, Adrienne O’Neil2,3, Dean P McKenzie3, Silva Zavarsek4,
Kristy Sanderson5, David L Hare6, Aaron J Fisher7, Andrew B Forbes3, C Barr Taylor8, David M Clarke9,
Ian T Meredith10 and Brian Oldenburg1Abstract
Background: Depression and anxiety are highly prevalent and co-morbid in acute coronary syndrome patients.
Somatic and cognitive subtypes of depression and anxiety in acute coronary syndrome have been shown to be
associated with mortality although their association with patient outcomes is unknown, as are the mechanisms
that underpin these associations. We are conducting a prospective cohort study which aims to examine in acute
coronary syndrome patients: (1) the role of somatic subtypes of depression and anxiety as predictors of health
related quality of life outcomes; (2) how somatic subtypes of depression and anxiety relate to long term vocational
functioning and healthcare utilisation; and (3) the role of the autonomic nervous system assessed by heart rate
variability as a moderator of these associations.
Methods: Patients are being screened after index admission for acute coronary syndrome at a single, high volume
centre, MonashHeart, Monash Health, Victoria, Australia. The inclusion criterion is all patients aged > 21 years old
and fluent in English admitted to MonashHeart, Monash Health with a diagnosis of acute coronary syndrome. The
primary outcome is mean health related quality of life (Short Form-36) Physical and Mental Health Summary scores
at 12 and 24 months in subtypes with somatic symptoms of depression and anxiety. Depressive domains are
assessed by the Beck Depression Inventory II and the Cardiac Depression Scale. Anxiety is measured using the
Speilberger State-Trait Anxiety Inventory and the Crown Crisp Phobic Anxiety questionnaire. Secondary outcomes
include clinical variables, healthcare service utilisation and vocational functioning.
Discussion: This manuscript presents the protocol for a prospective cohort study which will investigate the role of
somatic subtypes of depression and anxiety as predictors of health related quality of life, long-term vocational
functioning and health service use, and the role of the autonomic nervous system in moderating these associations.
Findings from the study have the potential to inform more effective pharmacological, psychological and behavioural
interventions and better guide health policy on the use of health care resources.
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After ACS, major depression has a prevalence of over
10%, about twice that found in the general population.
Less severe symptoms of depression are found in 20-
30% of patients after ACS, with similar prevalence rates
for anxiety [1-4]. Depression and anxiety have both been
shown to result in increased mortality and morbidity
[5-9], reduced HRQoL [10], poorer vocational outcomes
[11], and delays in returning to work [12]. Despite the
high prevalence of depression and anxiety the conditions
remain under-recognised, poorly diagnosed and under-
treated in ACS populations [13]. Emerging evidence
suggests that different combinations of symptoms, repre-
senting different subtypes of depression, may result in
different outcomes. For instance, there is evidence that
depression dominated by somatic symptoms may have
worse outcomes than depression dominated by cognitive
symptoms. Somatic subtypes of depression, (which in-
clude symptoms of fatigue, altered sleeping patterns or
changes in appetite) predict cardiovascular prognosis
[12] and all-cause mortality [13]. There are indications
that somatic subtypes of anxiety disorder may predict
coronary heart disease (CHD) [14]. Also, the anhedonia
(loss of pleasure or interest) component of depression
identifies risk of major adverse cardiac events and all-
cause mortality beyond that of major depressive episode
and depressive symptom severity in ACS patients [15].
Importantly, key depression subtypes, regardless of
whether or not diagnostic thresholds for a disorder are
satisfied, have the potential to predict important patient
outcomes such as long-term functioning and recovery
[16]. Patient outcomes are of particular importance
given that HRQoL has been shown to be as important
for ACS patients as any gains in survival [13]. Identifying
the key symptom subtypes related to these functional
outcomes has the potential to guide development and
delivery of more targeted and effective interventions.
Not surprisingly, the psychophysiological mechanisms
that underpin the relationships between different sub-
types of depression and patient outcomes also remain
poorly understood. Of particular significance is the role
of the autonomic nervous system. Heart rate variability
(HRV) reflects the normal healthy autonomically-regulated
beat-to-beat variation [17]. In general, healthy persons have
more variability in heart rate than unwell persons. Alter-
ations to normal HRV have been shown to be important
markers of prognosis among post-myocardial infarction
(MI) patients with both depressive and anxiety disorders
[18]. Indeed, there is now relatively strong evidence that
overall HRV is consistently lower in depressed patients
with CHD than in non-depressed patients with CHD
[19]. In a large study exploring the association between
HRV in patients after MI (n = 805), HRV was signifi-
cantly lower in the depressed patient group, comparedto the non-depressed group, even after adjusting for
possible confounders such as diabetes and smoking [20].
Furthermore, there is some evidence to suggest a vari-
ation in HRV abnormalities between different depression
subtypes in patients with CHD [21]. For example, depres-
sion dominated by somatic symptoms, including symptoms
of fatigue and psychomotor changes, have been associated
with reduced HRV while cognitive symptoms, such as
negative self-image, have not [22]. In addition, a smaller
group of studies have suggested HRV is lower in CHD pa-
tients with anxiety disorders, compared to those without
[18]. A recent review also found that HRV has clinically
significant prognostic value in depressed patients who have
had a recent MI [19]. However, few studies have investi-
gated the relationship between depression dominated by
somatic symptoms on patient outcomes such as HRQoL,
vocational functioning and health care utilisation. There is
also little evidence about whether HRV moderates these
associations, that is, alters the strength of the presumed
causal relationship between somatic subtypes of depression
and patient outcomes. This is a major gap in knowledge
given the importance of these outcomes to patients follow-
ing cardiac events.
In relation to patient outcomes, intervention studies
have shown improvements in HRQoL in ACS patients
with depression and anxiety. For example, the Managing
Co-morbid Depression: Coronary Aftercare Randomised
Evaluation (MOOD-CARE) [23] demonstrated improve-
ments in HRQoL following a telephone-counselling
program for the management of depression and CHD
secondary prevention for ACS patients. After six months
follow-up, the intervention resulted in statistically sig-
nificant improvements in Short Form 12 (SF-12) Mental
Component Summary scores (mean difference in change
between groups = 5.7; p = 0.041) for those with a history
of depression when compared with usual care [24].
Similarly, the Proactive Heart trial [25] used telephone
coaching risk factor management interventions in ACS
patients following a cardiac event. This trial also demon-
strated significant improvements in HRQoL as a result
of the intervention in the Mental Component Summary
score (p = 0.02), and the Social Functioning (p = 0.04)
and Role-Emotional (p = 0.03) subscales of the Short
Form 36 (SF-36) compared with usual care. However,
both studies used relatively brief measures of depression
and anxiety (e.g. Patient Health Questionnaire 9 in
MOOD-CARE; Hospital Anxiety and Depression Scale
in the Proactive Heart trial), which included few items
concerned with feelings of helplessness, worthlessness
and hopelessness. Additionally, neither study measured
HRV, thus precluding a thorough investigation of de-
pression and anxiety subtypes.
In relation to employment status and health care util-
isation, depression and anxiety have been found to be
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ing ACS [26]. For example, those experiencing depres-
sion report poorer rates of return to work following
ACS [27] as well as poorer productivity [12,28]. Simi-
larly, depression has also been associated with a 15% to
53% increase in 5-year cardiovascular costs in those with
myocardial ischaemia [29]. The presence of depressive
symptoms exhibited during a hospital stay have been as-
sociated with an increased rate of hospital readmissions
in medical patients [30]. However, much less is known
about healthcare utilisation in ACS patients where
symptoms of depression and anxiety occur co-morbidly.
A more comprehensive investigation of the predictive
relationship of symptom subtypes of depression and
anxiety in ACS patients with HRQoL, vocational func-
tioning and health care utilisation has not yet been
conducted. This paper presents the study protocol for a
prospective cohort study that is in progress. We hy-
pothesise that, ACS patients with the somatic symptom
subtype and lower HRV will: 1) report poorer HRQoL
(SF-36); 2) report poorer vocational outcomes; and 3)
exhibit differing patterns of healthcare service utilization
at 12 and 24 months compared to ACS patients without
the somatic subtype of depression and with higher levels
of HRV at baseline.
Methods
We are currently enrolling ACS patients into a prospect-
ive cohort study in which participants complete an
assessment at baseline, 12 and 24 months follow-up
(Figure 1).Total no. ACS ad
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Figure 1 Flow diagram of study.Study aims
In ACS patients, we aim to examine: (1) the role of som-
atic subtypes of depression and anxiety as predictors of
HRQoL outcomes; (2) how somatic subtypes of depres-
sion and anxiety relate to long term vocational function-
ing and healthcare utilisation; and (3) the role of the
autonomic nervous system assessed by HRV as a moder-
ator of these associations.
Study sample
Eligibility criteria
Eligibility criteria includes: (i) aged > 21 years old; (ii)
admitted to MonashHeart, Monash Health with a diag-
nosis of ACS (ST-elevation MI, non-ST-elevation MI or
unstable angina) within 4 weeks; (iii) an adequate under-
standing of English sufficient to complete the study.
Patients are excluded if they are: unable to give in-
formed consent, pregnant, cognitively impaired, report
substance abuse, have a terminal illness and/or other
illness that may impair participation, participating in
other trials.
Sample recruitment procedures
We are recruiting 550 ACS patients over 18 months
from the MonashHeart, Monash Health in the south-
eastern suburbs of Melbourne, Victoria (catchment
population ~1.2 million). This provides the largest
network of cardiac health services in Australia (>1340
ACS admissions/year). Participants are being recruited
between January 2013 and June 2014. Recruitment
is performed by study co-ordinators employed bymissions screened for
 years (MonashHeart) 
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screen admitted patients for eligibility by approaching
those deemed suitable, explaining the study and
obtaining informed consent. A letter is mailed to par-
ticipant’s primary care provider/s informing them of
the study aims and the participant’s agreement to enrol
in the study. Shortly after enrolment, participants are
sent a ‘welcome pack’ containing a welcome letter and
further details about the study. To facilitate a compari-
son of participants and non-participants, de-identified
demographic data (year of birth, sex, cardiac diagnosis
on admission) are being collected on the entire popula-
tion of eligible ACS patients identified during the study
period.
Primary endpoint and sample size calculation
Power and sample size calculations are based on detect-
ing differences in mean SF-36 Physical and Mental
Health Summary scores at 12 and 24 month follow-up
assessment between the symptom subgroups as deter-
mined by latent classes at baseline (see ‘Subtype classifi-
cation - latent classes’ paragraph and ‘Data analysis’
description below). A clinically significant change in
standardised (mean = 50, standard deviation (SD) = 10)
summary scores on the SF-36 is often regarded as 5
units [31] or an effect size of 0.50, corresponding to
what is by convention labelled a moderate effect size
[32]. Depression is generally associated with an even lar-
ger effect size. For example, a study of MI patients [33]
found a 10 unit (effect size = 1.0) difference in 12 month
SF-36 scores between those with low and high scores on
a measure of depression at baseline. Therefore, an ex-
pected effect size of 0.60 between the groups with the
lowest expected mean score (group 1), and that of each
of the three groups with the next lowest mean score
(groups 2, 3, 4), would appear to be reasonable, together
with an effect size of 1.0 between the lowest and highest
groups (1 and 5). With 5 latent classes there are 10 pair-
wise comparisons, therefore all comparisons are per-
formed using a 0.5% significance level to ensure an
overall Type I (false positive) error rate of 5% (Bonferroni
correction). The within-group SD is assumed to be
10 SF-36 units, as above. Since group 3 is expected to
be the smallest group size (15% of sample), sample size is
determined to have the comparison between groups 1
and 3 being able to detect a difference of 6 SF-36 units
with 80% power. This requires 88 patients in group 1
and 66 in group 3. From these numbers, the sizes of the
other groups are determined, resulting in a total of 440
completing patients being required. An expected attri-
tion rate of ~10% per year indicates that the number of
patients required to be recruited is ~550 (expected
group sizes would be 110, 137, 83, 110, 110 for groups
1–5, respectively) (Figure 1). These group sizes ensurethe power to detect a difference of at least 5 units is 92%
for a comparison between groups 1 and 2, 80% between
groups 1 and 3, and 88% between groups 1 and 4. An
effect size of 10 SF-36 units between groups 1 and 5 can
be detected with over 99.9% power. In terms of precision
of group comparisons, any pairwise comparison will
have a Bonferroni 95% confidence interval width of at
most +/− 3.5 SF-36 units. The detection of moderation
of the relationship between the 5 latent classes and SF-
36 by HRV will involve assessing the additional ex-
plained variation resulting from adding the appropriate
statistical interaction terms into a regression-model con-
taining the main effects of the latent classes and HRV.
Assuming conservatively that 10% of variation in SF-36
is explained via these main effects and other prognostic
covariates, the sample size of 440 completing subjects
has 80% power to detect an increase in explained vari-
ation of 2.4% from the addition of the (4 degrees of free-
dom) interaction terms. This corresponds to an effect
size of 0.027, which is conventionally regarded as small
[32]. For detection of variation across latent classes in
the employment status at 12 months or for a binary
health services utilisation measure, expected absolute
differences of the order of 20-25% between any pair of
latent classes (with Bonferroni correction) can be de-
tected with 80% power.
Ethics approval
The study has been approved by the Human Research
Ethics Committee at Monash Health (HREC Ref
12249B) and Monash University (Project Number
CF12/3610 – 2012001723).
Data collection and outcome measures
Baseline data are collected during admission for ACS
by the study co-ordinators (demographic data) and
Research Assistants (clinical data measured during
face-to-face clinic assessments as well as questionnaire
data collected by computer assisted telephone interview
(CATI)). Follow-up data (as at baseline) are being
collected by Research Assistants after 12 and 24 months
(Table 1).
Baseline
The following demographic data are collected during ad-
mission: age, sex, medical history including diagnosis on
admission and co-morbidities (including hypertension,
stroke, cancer, diabetes and mental illness). The presence
of atrial fibrillation, flutter, arrhythmia or insertion of a
permanent pacemaker is noted. Blood measurements
(fasting blood glucose, lipids (cholesterol, triglycerides,
high-density lipoprotein cholesterol (HDL-C), low dens-
ity lipoprotein cholesterol (LDL-C)), high sensitivity C-
Table 1 Measurements at baseline and during follow-up
Outcome variable Measurement tool/Data
collection method
Time-point
(months)
0 12 24
Primary outcome
Difference in mean HRQoL
(SF-36) Physical and Mental
Health Summary scores at
12 and 24 month follow-up
between the latent classes
of depression and anxiety
determined at baseline
Short Form 36 [47] ✓ ✓ ✓
✓ ✓ ✓
Secondary outcomes
Medical history
Co-morbidities Medical records ✓
Medications Self-report discharge scripts ✓ ✓ ✓
Clinical indicators
Serum lipids; HbA1c; FBG;
hs-CRP
Medical records ✓
Blood pressure; pulse Clinical assessment ✓ ✓ ✓
Waist circumference Clinical assessment ✓ ✓ ✓
Body Mass Index Clinical assessment ✓ ✓ ✓
Diabetes Self-report diagnosis; HbA1c ✓ ✓ ✓
Heart Rate Variability Clinical assessment ✓ ✓ ✓
Depression/anxiety
Current depressive
symptoms
BDI-II [40] & CDS [42] ✓ ✓ ✓
Current anxiety symptoms STAI-S & STAI-T [43] ✓ ✓ ✓
Phobic Anxiety Crown Crisp
Index[45]
✓ ✓ ✓
Depression/anxiety history CIDI- Auto 2.1 [50] ✓ ✓ ✓
Behavioural measures
Worry The Penn State Worry
Short Form [48]
✓ ✓ ✓
Sleep Insomnia Severity Index [49] ✓ ✓ ✓
Work related outcomes Self-report ✓ ✓ ✓
Economic measures
Preference-based measure
of HRQoL (SF-6D)
Short Form 36 [47] ✓ ✓ ✓
Health care utilisation Self-report ✓ ✓ ✓
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(HbA1C)) during admission are recorded.
Clinical measurements are collected during attendance
at a clinical assessment. These include anthropometry
(weight, height, body mass index, waist circumference),
blood pressure, pulse and heart rate variability. Medica-
tion history is collected from hospital discharge scripts
or from self-report of medications (verified by Research
Assistants using packets/boxes of medications brought
in by participants). CATIs are performed to collect
questionnaire data including socio-demographic data(country of birth, language spoke at home, medical
insurance cover, annual income band, highest education
qualification, employment at time of cardiac event);
BDI-II, CDS, STAI-Y, Crown Crisp Phobic Anxiety
questionnaire, SF-36, Penn State Worry Questionnaire
Short Form, Insomnia Severity Index and Composite
International Diagnostic Interview (CIDI). Data on employ-
ment functioning post-ACS and health care utilisation in
the previous 6 months is also collected.
Follow-up
Clinical measurements are collected during a face to face
clinical assessment at 12 and 24 months following dis-
charge from hospital. These are the same as those at
baseline. In addition, CATI’s are performed to collect
questionnaire data at 12 and 24 months which are the
same as at baseline except health care utilisation in
which data from the previous 12 months will be
recorded.
Details of the measurements
Blood measurements
Blood measurements include fasting blood glucose,
lipids, hs-CRP and HbA1C. Blood samples are assayed
by Monash Health Pathology. hs-CRP (mg/L) is
assayed by Roche/Hitachi Modular® System P. HDL-C
is being measured using a commercial enzymatic assay
using a Beckman Coulter DXC800 analyzer with
reagents supplied by Beckman Coulter Diagnostics
(Sydney, Australia). Triglycerides are being measured
by standard methods within Southern Health Pathology.
LDL-C is being calculated using the Friedewald Formula
[34]. HbA1C is assayed using high performance liquid
chromatography (ADAMS ARKRAY Glycohaemoglobin
analyzer HA8160, Integrated Sciences, Australia CV%
1.5- 1.7).
Anthropometry
Weight is measured to the nearest 0.1 kg on standing
digital scales (SECA 813 Digital Scales) placed on a level,
hard surface without shoes and in light clothing. Height is
measured using a wall mounted stadiometer. Body mass
index is calculated and World Health Organization cutoffs
applied namely, overweight ≥25 kg/m2; obese ≥30 kg/m2
[35]. Waist circumference is measured using a spring
loaded tape measure (SECA 201) at the mid-point between
the lower costal margin and the iliac crest and World
Health Organization cutoffs applied (increased risk men
94 cm; women 80 cm) [35,36].
Blood pressure
Blood pressure (BP) is measured using an automated
device (OMRON HEM 7221 Automatic BP Monitor)
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two readings of systolic and diastolic BP is used. Hyperten-
sion is defined using World Health Organization cut
off points namely, systolic BP ≥140 mmHg or diastolic
BP ≥90 mmHg [37]. The average of two readings of
pulse is recorded from the BP monitor.
Heart rate variability
HRV [38] is collected via an electrocardiograph (ECG)
recording [39]. A dedicated computer is used with AD
Instruments software (LabChart v7.3 for Windows) for
continuous beat-to-beat heart rate recording with detec-
tion of R waves at frequency of 1000 Hz. Ectopic beats,
artefacts, patients with atrial fibrillation, flutter, perman-
ent pacemakers in situ or with less than 95% acceptable
R-R intervals are excluded from the HRV analyses.
Heart rate variability recording & analysis:
 Participants are asked to avoid caffeine, heavy
physical activity, smoking and alcohol 10 hours
preceding the clinic visit. Participants are asked to
have breakfast or at least a snack approximately
1 hour before the clinic visit (protocol violations are
recorded however participants are not excluded if
these conditions are not met).
 Study procedures are explained to patients in
advance and they are asked to lie quietly and still
before and during the recording. All attempts are
made to ensure that testing is conducted in a
consistent environment as stressors such as arousal
level, temperature and circadian rhythm can alter
HRV measures. Temperature is standardised and
time of recording is documented. Patients are
connected to a three lead electrocardiogram (ECG)
in the supine position then rested for 10 minutes. A
20-minute ECG recording is then obtained.
 Data are converted to R-R intervals for time domain
measurement and power spectrum (frequency) ana-
lysis. Time domain measures include mean R-R
interval duration (RR (ms)) (in which the ‘R-R inter-
val duration’ is defined as the time period between
successive R waves), standard deviation of all normal
to normal R-R intervals (SDNN (ms)), the root
mean square of successive differences between
normal-to-normal R-R intervals (rMSSD (ms)). Fre-
quency domain measures are generated through fast
Fourier transformation to produce a power spectral
density curve (a plot of the frequency of the oscilla-
tions of variation in R-R interval duration against
the square of their amplitude): high frequency (ms2)
is area under the power spectral density curve from
0.15-0.50 Hz (vagal modulation) low frequency
(ms2) is area under the power spectral density
curve from 0.04-0.15 Hz (parasympathetic andsympathetic modulation). LF/HF ratio is also
calculated as a stronger measure of
sympathovagal balance.
Adjustments are made using artefact identification
software to flag potential artefact that are manually
reviewed (using Poincaré plots) and deleted if appro-
priate. All files are analysed in blinded fashion.Beck depression interview
The BDI-II is a twenty one item multiple choice self-
report inventory that provides an overall measure of
somatic and cognitive symptoms of depression. It is
designed for individuals aged 13 years and over and has
been used in cardiac populations [40]. It is composed of
items relating to symptoms of depression such as hope-
lessness and irritability, cognitions such as guilt or feel-
ings of being punished, as well as physical symptoms
such as fatigue, weight loss and lack of interest in sex.Cardiac depression scale
The CDS is a twenty six item questionnaire for assessing
depression in cardiac patients (alpha reliability coeffi-
cient 0.90) [41]. It correlates well with clinical rating and
with the BDI-II. Cognitive subscales will be used to
measure anhedonia (loss of interest or pleasure) and
hopelessness [42].Speilberger state-trait anxiety inventory
The STAI-Y is a widely used instrument to measure
transient and enduring levels of anxiety [43]. It has been
used to distinguish between anxiety and depression
symptoms and chronic or trait anxiety subtypes in car-
diac populations [44]. The instrument is divided into
two sections (STAI-S & STAI-T) each with twenty ques-
tions. It contains four point Likert response items per
question.Crown-crisp index of phobic anxiety
The Crown-Crisp Index of Phobic Anxiety is an eight
item questionnaire used to measure phobic anxiety [45].
Phobic anxiety has been strongly associated with risk of
fatal CHD [46].Health related quality of life
The SF-36 (Version 2) is a multipurpose, multidimen-
sional health status scale for measuring HRQoL. It
comprises eight scales measuring Physical Function,
Role Physical, Bodily Pain, General Health, Vitality,
Social Function, Role Emotional, and Mental Health
[47]. These scales are collapsed into two summary
scales, the Physical Component Scale (PCS) and the
Mental Health Component scale (MCS).
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The Penn State Worry Questionnaire Short Form is a
seven item instrument to measure worry [48]. It pos-
sesses high internal consistency and good test-retest
reliability.
Insomnia severity index
The Insomnia Severity Index is a seven item question-
naire to assess insomnia severity [49]. The psychometric
properties show it has adequate internal consistency and
is a reliable self-report measure to evaluate perceived
sleep difficulties. It is also a valid and sensitive measure
to detect changes in perceived sleep difficulties with
treatment.
Composite international diagnostic interview (CIDI)
The CIDI Auto version 2.1 is a computer-assisted, com-
prehensive, fully-standardized interview that can be used
to assess mental disorders and provide diagnoses accord-
ing to the definitions and criteria of the tenth revision of
the International Classification of Diseases (ICD-10)
(World Health Organization 1992, 1993) and the fourth
edition of the American Psychiatric Association’s Diagnostic
and Statistical Manual of Mental Disorders (DSM-IV)
(American Psychiatric Association 1994) [50]. It is designed
to be used by trained lay interviewers and is used in this
study to assess history of clinical diagnosis of depressive
and anxiety disorders.
Economic evaluation
Employment, medication and health services utilisation
are collected through both self-report data and linkage
with Medicare Australia, and Pharmaceutical Benefits
Scheme data. This allows us to identify the relationship
between particular depression and anxiety subtypes and
healthcare use and labour force outcomes. We are also
examining the relationship between HRQoL and labour
force outcomes. Additionally, the data are matched to
other population data to compare HRQoL differences.
Furthermore, we are using these data to calculate the
societal impact of these conditions/symptoms by linking
health care use, to labour force status and to HRQoL.
Subtype classification - latent classes
A recently developed statistical technique, latent class
analysis (LCA) [51], is used to determine depression/
anxiety subtypes. This has recently been employed with
somatic and cognitive symptoms of depression and anx-
iety in a variety of populations [51,52], including the
medically ill [16]. Unlike variable-centred approaches
such as factor analysis, LCA is a person-centred ap-
proach; it allows grouping of individuals into classes
(subtypes), on the basis of shared characteristics such as
depression and anxiety symptoms. It can therefore bereadily ascertained which particular individuals have cer-
tain combinations of symptoms. LCA allows probabilis-
tic assignment of each individual to each class although
in practice, individuals are often assigned to the class
with the highest probability [53]. Classes can be com-
pared on outcomes such as HRQoL and vocational
functioning, while controlling for risk factors such as
pre-ACS depression and anxiety, blood pressure, as well
as CIDI diagnoses of depression and anxiety. Based upon
prior latent class analyses of similar populations [16,54],
we expect to find five classes: 1) ‘low distress’ (low on all
or most dimensions), consisting of 20% of patients, 2)
‘anxiety but low depression’ (25%), 3) ‘predominantly
depression with somatic symptoms’ (15%), 4) ‘predomin-
antly depression with cognitive symptoms’ (20%), 5)
‘comorbid depression and anxiety’ (high on most or all
dimensions) (20% of patients).
Primary outcome
The primary outcome is difference in mean HRQoL
(SF-36) Physical and Mental Health Summary scores
at 12 and 24 months between latent class group 1
(‘low distress’ i.e. low somatic symptoms of depression
and anxiety assessed by BDI-II, CDS, Crown Crisp
and STAI-Y and high/normal HRV, consisting of 20%
of participants) and latent class group 3 (‘predominantly
depression with somatic symptoms’ and low HRV, 15% of
participants), determined at baseline. Secondary outcomes
include clinical variables, healthcare service utilisation and
vocational functioning.
Data analysis
Hypotheses 1–3 are utilising LCA of symptom subtypes
of depression and anxiety, as measured using the BDI-II,
CDS, Crown Crisp and STAI-Y [51]. The resulting clas-
ses of patients are then compared at baseline, 12 and
24 months on outcome measures including HRQoL,
health service utilisation and occupational functioning,
using appropriate regression techniques [55]. Moder-
ation of the effects of the LCA classes on outcomes by
HRV will be assessed with the inclusion of appropriate
interaction terms between LCA classes and HRV in the
regression models. Patterns of change in outcome over
time are assessed using generalized estimating equations
to account for the repeated measurements of individuals
over time. The employment and health resource out-
comes specified in hypotheses 2 and 3 are being mod-
elled using econometric techniques [56], to analyse the
relationship of latent classes defined by profiles of de-
pression/anxiety symptoms, with healthcare use and
vocational functioning. A separate analysis linking this
to patients’ healthcare service use is being explored
using systems of equations, where the relationship be-
tween variables is accounted for simultaneously, so the
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employment status, and health care utilisation can be
estimated at the same time, across time periods.
Discussion
Depression and anxiety in ACS patients pose a signifi-
cant burden to patients and health care services. Studies
investigating the association of cognitive and somatic
symptoms of depression and anxiety with long-term
quality of life and vocational outcomes in ACS patients
are lacking. Further, there is little data on the psycho-
physiological mechanisms underpinning these associa-
tions. This manuscript presents the protocol for a
prospective cohort study that will investigate the role of
somatic subtypes of depression and anxiety as predictors
of HRQoL, long-term vocational functioning and health
service use, and the role of the autonomic nervous sys-
tem in moderating these associations. A greater under-
standing of these associations is needed to develop more
effective pharmacological, psychological and behavioural
interventions and to better guide health policy on the
use of health care resources. The study is aligned with
Australian National Health Priorities seeking to address
mental illness and chronic diseases.
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